How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%. During the same period in the prior year, the firm earned ($0.48) earnings per share.

What other stocks do shareholders of Recro Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include TherapeuticsMD (TXMD) , Rigel Pharmaceuticals (RIGL) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Flexion Therapeutics (FLXN) , Nabriva Therapeutics (NBRV) , SCYNEXIS (SCYX) , Verastem (VSTM) , Corbus Pharmaceuticals (CRBP) and Ocular Therapeutix (OCUL) .

NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free REPH Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.47
▼
$2.11
52-Week Range: N/A

Volume: 141,800 shs
Average Volume: 126,298 shs
Market Capitalization: $117.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Recro Pharma alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Recro Pharma Stock (NASDAQ:REPH)

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

REPH Stock News Headlines

January 30, 2024 | wsj.com

Fuji Pharma Co. Ltd.

November 7, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Recro Pharma's earnings report

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

August 16, 2023 | theguardian.com

US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits

August 9, 2023 | markets.businessinsider.com

What Wall Street expects from Recro Pharma's earnings

August 3, 2023 | investing.com

Mankind Pharma Ltd (MNKI)

June 30, 2023 | bizjournals.com

Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps

June 24, 2022 | benzinga.com

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 20, 2022 | reuters.com

Societal CDMO Inc

March 22, 2022 | finanznachrichten.de

Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

March 22, 2022 | finance.yahoo.com

Is Recro Pharma (REPH) a Worthy Investment?

March 1, 2022 | benzinga.com

Recap: Recro Pharma Q4 Earnings

February 23, 2022 | finance.yahoo.com

Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

February 22, 2022 | finance.yahoo.com

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

January 26, 2022 | finance.yahoo.com

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

January 3, 2022 | finance.yahoo.com

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

December 8, 2021 | finance.yahoo.com

Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?

November 2, 2021 | finance.yahoo.com

Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

October 27, 2021 | finance.yahoo.com

Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka

September 21, 2021 | marketwatch.com

Recro Pharma Signs Renewable Energy Agreement with Georgia Power

September 21, 2021 | finance.yahoo.com

Recro Signs Renewable Energy Agreement With Georgia Power

September 16, 2021 | finance.yahoo.com

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

August 16, 2021 | bizjournals.com

Recro Pharma goes bicoastal with 'transformative' acquisition of San Diego firm for $50M

August 13, 2021 | marketwatch.com

Recro Pharma Buys San Diego-Based Irisys for $50 Million >REPH

August 13, 2021 | finance.yahoo.com

Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO

August 10, 2021 | finance.yahoo.com

Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO

See More Headlines

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2022
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:REPH
CUSIP: N/A
CIK: 1588972
Web: www.recropharma.com
Phone: (770) 534-8239
Fax: 484-395-2471
Employees: 185
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,370,000.00
Net Margins: -15.15%
Pretax Margin: -15.09%
Return on Equity: -56.66%
Return on Assets: -11.14%

Debt

Debt-to-Equity Ratio: 2.27
Current Ratio: 3.24
Quick Ratio: 2.74

Sales & Book Value

Annual Sales: $75.36 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.90 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 56,424,000
Free Float: 48,412,000
Market Cap: $117.93 million
Optionable: Optionable
Beta: 1.08

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

J. David Enloe
President, Chief Executive Officer & Director
Ryan D. Lake
Chief Financial Officer & Treasurer
Richard Sidwell
Chief Scientific Officer & Senior Vice President
Stephen Dress
Director-Information Technology
David Smithwick
Vice President-Technical Operations

Key Competitors

View All Competitors

REPH Stock Analysis - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?: Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%. During the same period in the prior year, the firm earned ($0.48) earnings per share.
What other stocks do shareholders of Recro Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP) and Ocular Therapeutix (OCUL).

This page (NASDAQ:REPH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Recro Pharma (REPH) Stock Price, News & Analysis

About Recro Pharma Stock (NASDAQ:REPH)

REPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

REPH Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info